There are currently 1198 clinical trials in Pittsburgh, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Pittsburgh, University of Pittsburgh Medical Center, Alleghany General Hospital and Children's Hospital of Pittsburgh UPMC. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis
Recruiting
Naltrexone is an FDA approved drug (for alcoholism) that has found widespread use "off-label" to treat pain and improve quality of life at much lower doses than are used for the approved indication. There are a few scientific studies in three conditions (fibromyalgia, Crohn's disease, and multiple sclerosis) that suggest that this drug has benefit and is safe. However, considering the extent of use in other conditions, and uncertainty about the mechanism of action study is needed in a diverse se... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Giant Cell Arteritis, Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis
REFLECTION: A Clinical Practice Learning Program for Galleri®
Recruiting
REFLECTION is a multi-center, prospective, non-interventional, cohort study that will enroll approximately 17,000 individuals who have opted to be screened with Galleri®, a blood-based, multi-cancer early detection (MCED) test in routine clinical settings. The purpose of the study is to understand the real-world experience of Galleri® in clinical settings.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
05/17/2024
Locations: VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania
Conditions: Early Detection of Cancer, Cancer
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
Recruiting
This is an international, multicenter, multi-arm, phase Ib, model-based dose-escalation study. The primary objectives of the study in each arm is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose limiting toxicities (DLTs) and to evaluate the clinical efficacy at the MTD of various combinations of pembrolizumab, pralatrexate and decitabine.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
05/17/2024
Locations: Allegheny Health Network, Pittsburgh, Pennsylvania
Conditions: PTCL, CTCL
Late Onset Alzheimer's Disease
Recruiting
The goal of this study is to is to focus on the genetic influences on Alzheimer's Disease (AD) risk. The investigators are looking for families and/or individuals (affected or unaffected) of any ethic background (African American, Caucasian, and Hispanics) with a family history of AD and willing to participate.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
05/15/2024
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Alzheimer Disease
Heart Attack Research Program- Imaging Study
Recruiting
The HARP study is a multi-center, diagnostic observational study employing standardized imaging protocols in patients with MINOCA (MI with Non Obstructive Coronary Arteries) to determine the underlying diagnosis in each participant. Participants will be followed for recurrent clinical events, every 6 months, for a maximum of 10 years.
Gender:
ALL
Ages:
Between 21 years and 99 years
Trial Updated:
05/14/2024
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Myocardial Infarction
Empagliflozin Treatment in Kidney Transplant Recipients
Recruiting
Kidney transplantation improves the health and quality of life for those Veterans with end stage kidney disease (ESKD). While early patient and graft survival are excellent, long-term outcomes continue to be challenging. Patient death with existing kidney graft function occurs in about half of all recipients over time. This is primarily due to the development of cardiovascular disease in a patient population with multiple preexisting cardiac disease risk factors. There has been little progress i... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
05/14/2024
Locations: VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania
Conditions: Kidney Transplant, Type 2 Diabetes
Pulmonary Hypertension Association Registry
Recruiting
The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Centers throughout the U.S. PHAR will determine how people with PAH and CTEPH are evaluated, tested, and treated, and will observe how well these participants do. The goal is to see if people with PH a... Read More
Gender:
ALL
Ages:
0 years and above
Trial Updated:
05/14/2024
Locations: Allegheny General Hospital, Pittsburgh, Pennsylvania +1 locations
Conditions: Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
Study of DF9001 in Patients With Advanced Solid Tumors
Recruiting
DF9001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express epidermal growth factor receptor (EGFR). The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eligible pa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: UMPC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Solid Tumor, Adult
A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)
Recruiting
This is a 10-year multi-center, global, observational study to further characterize the safety profile of pegvaliase, including hypersensitivity reactions, long-term safety and tolerability, and the effectiveness of the additional risk minimization measures (aRMMs) (European Union (EU) only) in subjects receiving pegvaliase for the treatment of PKU. Subjects for whom a clinical decision has been made that they will receive pegvaliase to treat their PKU within 30 days following the date of enroll... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/10/2024
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Phenylketonuria (PKU)
PARTNER 3 Trial - Aortic Valve-in-Valve
Recruiting
This study will assess the safety and effectiveness of the SAPIEN 3/SAPIEN 3 Ultra transcatheter heart valve (THV) in patients with a failing aortic bioprosthetic valve.
Gender:
ALL
Ages:
All
Trial Updated:
05/08/2024
Locations: Allegheny General Hospital, Pittsburgh, Pennsylvania
Conditions: Aortic Stenosis, Aortic Stenosis, Severe
Effectiveness of the On the Move Group Exercise Program to Improve Mobility in Community-dwelling Older Adults
Recruiting
The purpose of this study is to test the effectiveness of On the Move (OTM) in terms of improving mobility among 502 older adults in 44 senior community centers and to evaluate intervention fidelity, including adherence and competence, and the impact of organizational, instructor, and participant level factors on intervention fidelity.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
05/08/2024
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Mobility Limitation
MyPaTH Story Booth
Recruiting
The MyPaTH Story Booth will use an (audio) "document" approach to elicit in depth experiential knowledge or perspectives from patients and caregivers by recording their personal stories.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/06/2024
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Narrative Medicine